October 2013 HSCI Community Newsletter
The Harvard Stem Cell Matrix
Upcoming Events
Diabetes Think Tank
TODAY! 9:00AM-5:00PM

Single Cell Network Meeting
Oct. 22, 4:30PM-6:00PM

Cancer Program Symposium
Nov. 8, 8:00AM-12:00PM
New HSCI iPS Core Training
Human Pluripotent Stem Cell Culture: Feeder Versus
December 9-10, 2013
Media Mentions
Penn News
HSCI intern Rakesh Goli, who
spent his summer in the lab of Da-Zhi Wang, PhD, is profiled.
Recent HSCI Papers
Cell Stem Cell
Removing Reprogramming Roadblocks: Mbd3 Depletion
Allows Deterministic
iPSC Generation

Cell Stem Cell
Induction of Multipotential Hematopoietic Progenitors
from Human Pluripotent Stem
Cells via Respecification of
Lineage-Restricted Precursors

Kidney International
Lineage-tracing Methods
and the Kidney
HSCI's First Clinical Trial
Leonard Zon, MD, and Corey Cutler, MD, MPH, complete Phase Ib trial of a molecule that expands hematopoietic stem cells.


Starting with a discovery in zebrafish in 2007, Harvard Stem Cell Institute researchers have published initial results of a Phase Ib human clinical trial of a therapeutic that has the potential to improve the success of blood stem cell transplantation. This marks the first time, just nine short years after Harvard's major commitment to stem cell biology, that investigators have carried a discovery from the lab bench to the clinic-fulfilling the promise on which HSCI was founded. Continue reading


 Read the paper in Blood.
Stem Cells Engineered to Become Targeted Drug Factories
Jeff Karp, PhD, manipulates mesenchymal stem cells to target and reduce inflammation in mice.


The researchers inserted modified strands of messenger RNA into mesenchymal stem cells, which stimulated the cells to produce adhesive surface proteins and secrete interleukin-10, an anti-inflammatory molecule. When injected into the bloodstream of a mouse, these modified human stem cells were able to target and stick to sites of inflammation and release biological agents that successfully reduced the swelling. Continue reading


Read the paper in Blood.
Genes Protect Themselves Against Being Silenced
Dan Tenen, PhD, discovers DNMT1-binding "extracoding RNA."


HSCI researchers have settled a century-old debate over whether occurrence of DNA methylation acts to silence gene expression, or if genes are turned off by other means before they are methylated. Continue reading


Read the paper in Nature.
Member News
  • Amy Wagers, PhD, receives New York Stem Cell Foundation-Robertson Stem Cell Prize. 
  • Douglas Melton, PhD, collaborates with Evotec to find pathways and signals that could be therapeutically relevant in diabetes. 
  • Pier Paolo Pandolfi MD, PHD, to head Cancer Center at Beth Israel Deaconess Medical Center.
  • Peng Yi, PhD, joins Joslin Diabetes Center's Islet Cell and Regenerative Biology Section.  
  • Diane Carlone, PhD, of Boston Children's Hospital joins HSCI as an Affiliated Faculty member.